APA (7th ed.) Citation

Goldstein, L. J., Zhao, F., Wang, M., Swaby, R. F., Sparano, J. A., Meropol, N. J., . . . Sledge, G. W. (2017). A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1104). Breast cancer research and treatment, 165(2), 375-382. https://doi.org/10.1007/s10549-017-4310-9

Chicago Style (17th ed.) Citation

Goldstein, Lori J., et al. "A Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination with Trastuzumab (Herceptin) in Patients with Advanced Metastatic And/or Local Chest Wall Recurrent HER2-amplified Breast Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E1104)." Breast Cancer Research and Treatment 165, no. 2 (2017): 375-382. https://doi.org/10.1007/s10549-017-4310-9.

MLA (9th ed.) Citation

Goldstein, Lori J., et al. "A Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination with Trastuzumab (Herceptin) in Patients with Advanced Metastatic And/or Local Chest Wall Recurrent HER2-amplified Breast Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E1104)." Breast Cancer Research and Treatment, vol. 165, no. 2, 2017, pp. 375-382, https://doi.org/10.1007/s10549-017-4310-9.